PRN: Global $17.85 Billion Insulin Delivery Devices Market 2017 by Type and End User - Forecast to 2021 - Research and Markets

12/mag/2017 12:15:11 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global $17.85 Billion Insulin Delivery Devices Market 2017 by Type and End User - Forecast to 2021 - Research and Markets

 
[12-May-2017]
 

DUBLIN, May 12, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Insulin Delivery Devices Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (External/Tethered, Patch), Pen Needles (Standard, Safety), Insulin Syringes) and End User (Patients/Homecare, Hospitals & Clinics) - Global Forecast to 2021" report to their offering.

Research and Markets Logo

The insulin delivery devices market is projected to reach USD 17.85 Billion by 2021 from 11.54 Billion in 2016, growing at a CAGR of 9.1% during the forecast period.

The major drivers in the market include favorable reimbursement scenario and government support in selected countries, technological advancements in insulin delivery devices, and growing diabetic population.

In 2016, the insulin pens segment accounted for the largest share of the global insulin delivery devices market. The insulin pens segment is further divided into reusable pens and disposable pens. In 2016, the reusable segment commanded the largest share of insulin pens market. The pumps segment is further segmented into external/ tethered pumps and patch pumps. In 2016, the external/tethered pumps segment accounted for the largest share of the insulin pumps market. Increasing prevalence of type 1 diabetes, rising diabetic healthcare expenditure, and availability of reimbursement are the factors attributing to the growth of this segment.

In 2016, the patients/homecare segment commanded the largest share of the insulin delivery devices market and is! expected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to the increasing diabetic population and rising healthcare expenditure.

The large share of this segment can be attributed to the rising prevalence of diabetes and favorable reimbursement scenario in the U.S. and Canada, growing venture capital investments and issuance of IPOs in the U.S., and FDA approvals to increase the commercial availability of insulin delivery devices in the U.S.

Key Topics Covered:

1 Introduction 

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Insulin Delivery Devices Market, By Type

7 Insulin Delivery Devices Market, By End User

8 Insulin Delivery Devices Market, By Region

9 Competitive Landscape

10 Company Profiles

  • Animas Corporation (Johnson and Johnson)
  • Becton, Dickinson and Company
  • Biocon Limited
  • ELI Lilly and Company
  • Insulet Corporation
  • Medtronic PLC
  • Novo Nordisk A/S
  • Sanofi
  • Tandem Diabetes Care, Inc.
  • Ypsomed Holding AG

For more information about this report visit http://www.researchandmarkets.com/research/6p52kl/insulin_delivery

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl